Ian Clark - Guardant Health Lead Independent Director
| GH Stock | USD 16.67 0.28 1.71% |
Director
Mr. Ian T. Clark is Lead Independent Director of the Company. Mr. Clark has served as a member of our board of directors since December 2016 and is our lead independent director. Mr. Clark currently serves on the boards of directors of Corvus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and other privatelyheld companies, including Forty Seven, Inc. He has also served as a member of Forty Seven, Inc.s audit committee since May 2018. Previously, Mr. Clark served on the board of directors of Shire Pharmaceuticals, Inc. from February 2017 to January 2019. He served on the board of directors and audit committee of Kite Pharma, Inc. from January 2017 to October 2017. He served as Chief Executive Officer of Genentech Inc. from January 2010 to December 2016. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, Mr. Clark held several senior management positions at Genentech Inc. from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Before joining Genentech Inc., Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Inc. and Sanofi S.A. in the United Kingdom, France and Eastern Europe. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporationrationration, holding positions in sales and marketing since 2016.
| Age | 57 |
| Tenure | 8 years |
| Address | 3100 Hanover Street, Palo Alto, CA, United States, 94304 |
| Phone | 855 698 8887 |
| Web | https://guardanthealth.com |
Ian Clark Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ian Clark against Guardant Health stock is an integral part of due diligence when investing in Guardant Health. Ian Clark insider activity provides valuable insight into whether Guardant Health is net buyers or sellers over its current business cycle. Note, Guardant Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Guardant Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ian Clark over three weeks ago Acquisition by Ian Clark of 15000 shares of Corvus Pharmaceuticals at 2.74 subject to Rule 16b-3 |
Guardant Health Management Efficiency
The company has Return on Asset (ROA) of (0.1764) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1764. This is way below average. Likewise, it shows a return on total equity (ROE) of (4.3813) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.37. As of now, Guardant Health's Debt To Assets are increasing as compared to previous years. The Guardant Health's current Fixed Asset Turnover is estimated to increase to 2.51, while Total Assets are projected to decrease to under 1.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Francis deSouza | Illumina | 53 | |
| Jan Johannessen | Twist Bioscience Corp | 62 | |
| Martin Harris | Thermo Fisher Scientific | 61 | |
| Lawrence Best | Myriad Genetics | 68 | |
| Nelson Chan | Twist Bioscience Corp | 57 | |
| Rebecca Chambers | Illumina | N/A | |
| Roy Whitfield | Illumina | 63 | |
| Robert Chess | Twist Bioscience Corp | 61 | |
| Karin Eastham | Illumina | 67 | |
| Teri ListStoll | Danaher | 58 | |
| Paul Conley | Twist Bioscience Corp | 49 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Heidi Fields | Agilent Technologies | 60 | |
| Jeffrey Huber | Illumina | 46 | |
| William Parrett | Thermo Fisher Scientific | 71 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Frederick Craves | Twist Bioscience Corp | 72 | |
| George Scangos | Agilent Technologies | 72 | |
| Sue Rataj | Agilent Technologies | 63 | |
| John Schwieters | Danaher | 81 | |
| Louise Phanstiel | Myriad Genetics | 59 | |
Management Performance
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 |
Guardant Health Leadership Team
Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AmirAli Talasaz, President COO, Director | ||
| Richard Lanman, Chief Medical Officer | ||
| Marcel Roche, Vice President - Finance | ||
| Ian Clark, Lead Independent Director | ||
| Leena DasYoung, General Manager,Chief LUNAR Officer | ||
| John Saia, Chief Secretary | ||
| DEREK BERTOCCI, CFO | ||
| Terilyn Monroe, Chief Officer | ||
| Craig MD, Chief Officer | ||
| Andy Ament, VP Operations | ||
| Kumud Kalia, Chief Officer | ||
| Michael Bell, Chief Officer | ||
| Michael Wiley, Chief Legal Officer | ||
| Aaref Hilaly, Independent Director | ||
| Darl Moreland, Senior Quality | ||
| Jennifer Higgins, Vice Affairs | ||
| Dipchand Nishar, Independent Director | ||
| Christopher Freeman, Chief Officer | ||
| Helmy Eltoukhy, CoCEO CoFounder | ||
| Mark Jacobstein, Chief User Engagement Officer | ||
| Bahija Jallal, Director | ||
| Stanley Meresman, Independent Director | ||
| Lynn Lewis, IR Contact Officer | ||
| Darya Chudova, VP Technology | ||
| Samir Kaul, Independent Director |
Guardant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.85) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 2.15 B | ||||
| Shares Outstanding | 121.71 M | ||||
| Shares Owned By Insiders | 4.14 % | ||||
| Shares Owned By Institutions | 93.70 % | ||||
| Number Of Shares Shorted | 7.64 M | ||||
| Price To Earning | (12.01) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.036 | Quarterly Revenue Growth 0.222 | Return On Assets (0.18) | Return On Equity (4.38) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.